Anti-CNTN4 Monoclonal Antibody GENA-104A16 clinical trials
Its developmentBy BioInvent International AB and Genome, step by step3 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses Anti-CNTN4 Monoclonal Antibody GENA-104A16 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Anti-CD32B Monoclonal Antibody BI-1607 (2)
Studies
Open first, then newest update. How each study uses Anti-CNTN4 Monoclonal Antibody GENA-104A16 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic MelanomaActive, not recruitingPhase 1/2BioInvent International ABNCT06784648Written as BI-1607How we know
- A First-in-human Study of GENA-104A16 in Patients With Advanced Solid TumorsWithdrawnPhase 1Genome & CompanyNCT06235541Written as GENA-104A16How we know
- BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid TumorsTerminatedPhase 1/2BioInvent International ABNCT05555251Written as BI-1607How we know